Halozyme Therapeutics (HALO) Other Working Capital Changes (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Other Working Capital Changes of $2.6 million for Q4 2023, up 213.81% year-over-year from $821827.3 in Q4 2022, and up 1573.71% quarter-over-quarter from -$175000.0 in Q3 2023.
Halozyme Therapeutics (HALO) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Other Working Capital Changes for 7 consecutive years, with $2.6 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Other Working Capital Changes rose 213.81% year-over-year to $2.6 million; the TTM figure through Dec 2024 stood at $2.4 million (changed N/A YoY), while the FY2022 annual figure was -$2.5 million, down 83033.33% from the prior year.
- Other Working Capital Changes grew to $2.6 million in Q4 2023 per HALO's latest filing, from -$175000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $43.5 million in Q2 2024 and bottomed at -$38.5 million in Q3 2024.
- Historically, Other Working Capital Changes has averaged $2.5 million across 5 years, with a median of $1.2 million in 2023.
- Annual changes were most pronounced in 2019 — Other Working Capital Changes soared 650.0% — and 2021, when it slumped 16500.0%.
- Halozyme Therapeutics' Other Working Capital Changes stood at -$6000.0 in 2019, then jumped by 50.0% to -$3000.0 in 2020, then jumped by 33233.33% to $994000.0 in 2021, then slumped by 327.97% to -$2.3 million in 2022, then soared by 213.81% to $2.6 million in 2023.
- Business Quant data shows HALO's Other Working Capital Changes at $2.6 million in Q4 2023, -$175000.0 in Q3 2023, and -$2.4 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.15 Mn |
| Jun 30, 2026 | 41.15 Mn |
| Jun 30, 2026 | 41.15 Mn |
| Mar 31, 2026 | 9.11 Mn |
| Mar 31, 2026 | 9.11 Mn |
| Mar 31, 2026 | 9.11 Mn |
| Dec 31, 2025 | -28.42 Mn |
| Dec 31, 2025 | -28.42 Mn |
| Dec 31, 2025 | -28.42 Mn |
| Sep 30, 2025 | 20.32 Mn |
| Sep 30, 2025 | 20.32 Mn |
| Sep 30, 2025 | 20.32 Mn |
| Jun 30, 2025 | 36.07 Mn |
| Jun 30, 2025 | 36.07 Mn |
| Jun 30, 2025 | 36.07 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Dec 31, 2024 | -5.62 Mn |
| Dec 31, 2024 | -5.62 Mn |